Method development and validation of LC-MS/MS-based assay for the simultaneous quantitation of trastuzumab and pertuzumab in cynomolgus monkey serum and its application in pharmacokinetic study.


Journal

Biomedical chromatography : BMC
ISSN: 1099-0801
Titre abrégé: Biomed Chromatogr
Pays: England
ID NLM: 8610241

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 05 04 2020
revised: 12 05 2020
accepted: 15 05 2020
pubmed: 20 5 2020
medline: 20 4 2021
entrez: 20 5 2020
Statut: ppublish

Résumé

We present a simple and robust LC-MS/MS assay for the simultaneous quantitation of an antibody cocktail of trastuzumab and pertuzumab in monkey serum. The LC-MS/MS method saved costs, decreased the analysis time, and reduced quantitative times relative to the traditional ligand-binding assays. The serum samples were digested with trypsin at 50°C for 60 min after methanol precipitation, ammonium bicarbonate denaturation, dithiothreitol reduction, and iodoacetamide alkylation. The tryptic peptides were chromatographically separated using a C18 column (2.1 × 50 mm, 2.6 μm) with mobile phases of 0.1% formic acid in water and acetonitrile. The other monoclonal antibody, infliximab, was used as internal standards to minimize the variability during sample processing and detection. A unique peptide for each monoclonal antibody was simultaneously quantified using LC-MS/MS in the multiple reaction monitoring mode. Calibration curves were linear from 2.0 to 400 μg/mL. The intra- and inter-assay precision (%CV) was within 8.9 and 7.4% (except 10.4 and 15.1% for lower limit of quantitation), respectively, and the accuracy (%Dev) was within ±13.1%. The other validation parameters were evaluated, and all results met the acceptance criteria of the international guiding principles. Finally, the method was successfully applied to a pharmacokinetics study after a single-dose intravenous drip administration to cynomolgus monkeys.

Identifiants

pubmed: 32428305
doi: 10.1002/bmc.4903
doi:

Substances chimiques

Antibodies, Monoclonal, Humanized 0
pertuzumab K16AIQ8CTM
Trastuzumab P188ANX8CK

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e4903

Subventions

Organisme : National Major Scientific and Technological Special Project for "Significant New Drugs Development"
ID : 2020ZX09201026

Informations de copyright

© 2020 John Wiley & Sons, Ltd.

Références

Ackermann, B., Neubert, H., Hughes, N., Garofolo, F., Abberley, L., Alley, S. C., … Witte, B. (2015). 2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 2-hybrid LBA/LCMS and input from regulatory agencies). Bioanalysis, 7(23), 3019-3034. https://doi.org/10.4155/bio.15.214
Albanell, J., Montagut, C., Jones, E. T., Pronk, L., Mellado, B., Beech, J., … Valle, J. W. (2008). A Phase I Study of the Safety and Pharmacokinetics of the Combination of Pertuzumab (rhuMab 2C4) and Capecitabine in Patients with Advanced Solid Tumors. Clinical Cancer Research, 14(9), 2726-2731. https://doi.org/10.1158/1078-0432.CCR-07-1980
Bults, P., Bischoff, R., Bakker, H., Gietema, J., & van de Merbel, N. (2015). LC-MS/MS-based monitoring of in vivo protein biotransformation: quantitative determination of trastuzumab and its deamidation products in human plasma. Analytical Chemistry, 88(3), 1871-1877. https://doi.org/10.1021/acs.analchem.5b04276
Guidance for industry bioanalytical method validation. [FDA web site], Available at: https://www.fda.gov/downloads/drugs/guidances/ucm070107.pdf, (2018). (Accessed 18 February 2019)
Haulenbeek, J., & Piccoli, S. P. (2014). Conjugated critical reagent characterization for ligand-binding assays: using MALDI-TOF-MS as an orthogonal tool to assess assay performance. Bioanalysis, 6(7), 983-992. https://doi.org/10.4155/bio.14.65
Iwamoto, N., Takanashi, M., Hamada, A., & Shimada, T. (2016). Validated LC/MS Bioanalysis of Rituximab CDR Peptides Using Nano-surface and Molecular-Orientation Limited (nSMOL) Proteolysis. Biological & Pharmaceutical Bulletin, 39(7), 1187-1194. https://doi.org/10.1248/bpb.b16-00230
Jenkins, R., Duggan, J. X., Aubry, A.-F., Zeng, J., Lee Jean, W., Cojocaru, L., … Vazvaei, F. (2015). Recommendations for Validation of LC-MS/MS Bioanalytical Methods for Protein Biotherapeutics. The AAPS Journal, 17(1), 1-16. https://doi.org/10.1208/s12248-014-9685-5
Jiang, H., Zeng, J., Titsch, C., Voronin, K., Akinsanya, B., Luo, L., … Arnold, M. (2013). Fully Validated LC-MS/MS Assay for the Simultaneous Quantitation of Coadministered Therapeutic Antibodies in Cynomolgus Monkey Serum. Analytical Chemistry, 85(20), 9859-9867. https://doi.org/10.1021/ac402420v
Kleinnijenhuis, A. J., Ingola, M., Toersche, J. H., van Holthoon, F. L., & van Dongen, W. D. (2016). Quantitative bottom up analysis of infliximab in serum using protein A purification and integrated μLC-electrospray chip IonKey MS/MS technology. Bioanalysis, 8(9), 891-904. https://doi.org/10.4155/bio-2015-0015
Kowalczyk, L., Bartsch, R., Singer, C. F., & Farr, A. (2017). Adverse Events of Trastuzumab Emtansine (T-DM1) in the Treatment of HER2-Positive Breast Cancer Patients. Breast Care, 12, 401-408. https://doi.org/10.1159/000480492
Li, F., Fast, D., & Michael, S. (2011). Absolute quantitation of protein therapeutics in biological matrices by enzymatic digestion and LC-MS. Bioanalysis, 3(21), 2459-2480. https://doi.org/10.4155/bio.11.237
Li, H., Ortiz, R., Tran, L., Hall, M., Spahr, C., Walker, K., … Lee, J. W. (2012). General LC-MS/MS Method Approach to Quantify Therapeutic Monoclonal Antibodies Using a Common Whole Antibody Internal Standard with Application to Preclinical Studies. Analytical Chemistry, 84(3), 1267-1273. https://doi.org/10.1021/ac202792n
Li, H., Ortiz, R., Tran, L. T. B., Salimi-Moosavi, H., Malella, J., James, C. A., & Lee, J. W. (2013). Simultaneous Analysis of Multiple Monoclonal Antibody Biotherapeutics by LC-MS/MS Method in Rat Plasma Following Cassette-Dosing. The AAPS Journal, 15(2), 337-346. https://doi.org/10.1208/s12248-012-9435-5
Liu, N., Tengstrand, E., Boernsen, O., Stephan, B., & Frank, H. (2019). Validation of a multiplexed LC-MS/MS clinical assay to quantify insulin growth factor binding proteins in human serum and its application in a clinical study. Toxicology and Applied Pharmacology, 371, 74-83. https://doi.org/10.1016/j.taap.2019.03.024
O'Sullivan, C. C., & Swain, S. M. (2013). Pertuzumab: evolving therapeutic strategies in the management of HER2-overexpressing breast cancer. Expert Opinion on Biological Therapy, 13(5), 779-790. https://doi.org/10.1517/14712598.2013.783007
Sendur, M. A., Aksoy, S., & Altundag, K. (2012). Pertuzumab in HER2-positive breast cancer. Current Medical Research and Opinion, 28(10), 1709-1716. https://doi.org/10.1185/03007995.2012.728132
Swain, S. M., Baselga, J., Kim, S. B., Ro, J., Semiglazov, V., Campone, M., … Cortés, J. (2015). Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine, 372(8), 724-734. https://doi.org/10.1056/NEJMoa1413513
Wang, Q., Han, J., Sha, C., Liang, Y., Sun, Y., Shao, X., … Liu, W. (2017). Novel strategy using tryptic peptide immunoaffinity-based LC-MS/MS to quantify denosumab in monkey serum. Bioanalysis, 9(19), 1451-1463. https://doi.org/10.4155/bio-2017-0106
Willeman, T., Jourdil, J.-F., Gautier-Veyret, E., Bonaz, B., & Stanke-Labesque, F. (2019). A multiplex liquid chromatography tandem mass spectrometry method for the quantification of seven therapeutic monoclonal antibodies: Application for adalimumab therapeutic drug monitoring in patients with Crohn's disease. Analytica Chimica Acta, 1067, 63-70. https://doi.org/10.1016/j.aca.2019.03.033
Yang, Y. M., Cheng, Y. G., Che, J. J., Chen, Z. H., Liu, Y. L., Hu, B. H., … Zhang, M. T. (2016). Pharmacokinetics of Pertuzumab in the Body of the Cynomolgus Monkey. Letters in Biotechnology, 27(02), 233-236.
Yang, Z., Hayes, M., Fang, X., Daley, M. P., Ettenberg, S., & Tse, F. L. (2007). LC-MS/MS Approach for Quantification of Therapeutic Proteins in Plasma Using a Protein Internal Standard and 2D-Solid-Phase Extraction Cleanup. Analytical Chemistry, 79(24), 9294-9301. https://doi.org/10.1021/ac0712502
Zhang, Y. J., Olah, T. V., & Zeng, J. (2014). The integration of ligand binding and LC-MS-based assays into bioanalytical strategies for protein analysis. Bioanalysis, 6(13), 1827-1841. https://doi.org/10.4155/bio.14.128

Auteurs

Luo-Lan Gui (LL)

School of Chemical Engineering, Tianjin University, Tianjin, China.
State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, China.
Beijing United-Power Pharma Tech Co., Ltd., Beijing, China.

Li Li (L)

State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, China.
Beijing United-Power Pharma Tech Co., Ltd., Beijing, China.

Li-Hou Dong (LH)

State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, China.
Beijing United-Power Pharma Tech Co., Ltd., Beijing, China.

Shen-Si Xiang (SS)

State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, China.

Jian-Ping Zhai (JP)

School of Chemical Engineering, Tianjin University, Tianjin, China.
State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, China.
Beijing United-Power Pharma Tech Co., Ltd., Beijing, China.

Zhi-Qiang Ge (ZQ)

School of Chemical Engineering, Tianjin University, Tianjin, China.

Hai-Feng Song (HF)

State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, China.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH